Sevelamer hydrochloride
Pro Research Analysisby 
Searched over 200M research papers for "sevelamer hydrochloride"
Sevelamer Hydrochloride: Efficacy, Safety, and Clinical Implications
Introduction to Sevelamer Hydrochloride
Sevelamer hydrochloride is a non-calcium, non-metal phosphate binder used primarily in patients undergoing dialysis to manage hyperphosphatemia. It is particularly beneficial in preventing hypercalcemia, a common side effect associated with calcium-based phosphate binders Sadek2003Bleyer1999. This article synthesizes recent research on the efficacy, safety, and clinical implications of sevelamer hydrochloride in dialysis patients.
Efficacy in Phosphate Control
Comparison with Calcium-Based Binders
Sevelamer hydrochloride has been shown to effectively control serum phosphate levels in dialysis patients, comparable to calcium-based binders like calcium carbonate and calcium acetate. Studies indicate that both sevelamer and calcium-based binders significantly reduce serum phosphate levels, but sevelamer has the added advantage of not increasing serum calcium levels, thereby reducing the risk of hypercalcemia Sadek2003Bleyer1999Evenepoel2008. In a randomized study, sevelamer hydrochloride was as effective as calcium acetate in lowering serum phosphate, with a significant reduction in hypercalcemia incidence (5% vs. 22%) .
Impact on Vitamin D and Parathyroid Hormone
Research comparing sevelamer hydrochloride with calcium carbonate found no significant difference in the control of plasma calcium, phosphate, and 25-OH vitamin D levels. Both treatments resulted in an increase in parathyroid hormone (PTH) levels, indicating comparable efficacy in managing moderate hyperparathyroidism .
Safety and Side Effects
Metabolic Acidosis and Gastrointestinal Issues
One of the notable side effects of sevelamer hydrochloride is its potential to cause metabolic acidosis. Studies have shown that sevelamer hydrochloride can decrease serum bicarbonate levels, which may not be ideal for patients at risk of acidosis. In contrast, sevelamer carbonate, a newer formulation, does not have this effect and may be more suitable for such patients Fishbane2010Pai2009. Gastrointestinal side effects, including nausea and vomiting, have also been reported, particularly with the powder form of sevelamer carbonate .
Cardiovascular Benefits
Sevelamer hydrochloride has been associated with cardiovascular benefits, including a reduction in low-density lipoprotein (LDL) cholesterol levels. This lipid-lowering effect may provide an advantage in cardiovascular disease prevention among dialysis patients Sadek2003Bleyer1999Evenepoel2008. A meta-analysis indicated that sevelamer significantly reduces coronary artery calcification scores compared to calcium-based phosphate binders, suggesting a potential benefit in reducing cardiovascular calcification .
Anti-Inflammatory and Antioxidant Effects
Sevelamer hydrochloride has demonstrated anti-inflammatory and antioxidant benefits. A study found that patients treated with sevelamer hydrochloride showed a significant decrease in pro-inflammatory cytokines (IL-6 and TNF-α) and oxidative stress markers, suggesting a protective effect against inflammation and oxidative damage .
Clinical Implications
Bone Health
Sevelamer hydrochloride has been shown to positively impact bone health. In a year-long study, patients treated with sevelamer exhibited an increase in bone formation rate and improvement in trabecular architecture, although no significant changes in bone turnover or mineralization were observed compared to calcium carbonate .
Drug Interactions
Sevelamer hydrochloride can affect the oral bioavailability of certain medications. For instance, it significantly decreases the bioavailability of ciprofloxacin, which may reduce the antibiotic's clinical efficacy and promote bacterial resistance .
Conclusion
Sevelamer hydrochloride is an effective phosphate binder for dialysis patients, offering benefits in controlling serum phosphate without increasing the risk of hypercalcemia. It also provides cardiovascular, anti-inflammatory, and antioxidant benefits. However, its potential to cause metabolic acidosis and gastrointestinal side effects, as well as its interaction with other medications, should be carefully considered in clinical practice. Further research is warranted to explore its long-term effects on clinical outcomes such as fracture rates and overall mortality.
Sources and full results
Most relevant research papers on this topic
Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
Sevelamer hydrochloride is as effective as calcium carbonate in controlling moderate hyperparathyroidism in dialysis patients, with potential advantages in cardiovascular prevention due to its decrease in LDL cholesterol.
DOI
The Influence of Sevelamer Hydrochloride and Calcium Carbonate on Markers of Inflammation and Oxidative Stress in Hemodialysis at Six Months of Follow-Up
Sevelamer hydrochloride effectively manages hyperphosphatemia in ESRD patients, with anti-inflammatory and antioxidant benefits, while calcium carbonate increases inflammation markers.
Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Sevelamer hydrochloride effectively reduces serum phosphorus levels in peritoneal dialysis patients, with similar effects to calcium-based binders, and is well-tolerated and safe.
DOI
Comparison of Sevelamer Hydrochloride and Sevelamer Carbonate: Risk of Metabolic Acidosis and Clinical Implications
Sevelamer carbonate is more appropriate for patients at risk for metabolic acidosis who require phosphate binders without calcium or aluminum, as it does not decrease serum bicarbonate levels.
Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.
Sevelamer hydrochloride increased bone formation and improved trabecular architecture in hemodialysis patients, but did not significantly change bone turnover or mineralization compared to calcium carbonate.
A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
JTT-751 is as effective and safe as sevelamer in reducing serum phosphate levels in hemodialysis patients with hyperphosphatemia, but may cause more diarrhea.
DOI